REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step ...

Nonnucleoside Reverse-transcriptase Inhi... Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic ...

Background. The presence of transmitted drug resistance mutations (TDRMs) in antiretroviral treatment (ART)–naive patients can adversely affect the outcome of ART. Methods. Resistance testing was ...

Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer PURPOSE: Reverse transcription-polymerase chain reaction ...

PURPOSE: Inconsistent conclusions have been drawn about the clinical significance of micrometastases in lymph nodes (LNs) of node-negative colorectal cancer (CRC) patients. We performed a comparative ...